Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials

EuroIntervention. 2009 Sep;5(4):475-84. doi: 10.4244/eijv5i4a76.

Abstract

Aims: We sought to determine if outcomes differ between provisional (elective side branch stenting) compared to a routine two-stent strategy (mandatory side branch stenting) for the treatment of bifurcation stenoses of the coronary arteries using drug-eluting stents.

Methods and results: We searched Medline, EMBASE, and the Cochrane library from January 2000 to February 2009 for studies comparing the provisional and two-stent strategies. Six randomised controlled trials, including 1,641 patients, were identified. The relative risk (95% confidence interval) for death, MI, target lesion revascularisation, and stent thrombosis within 1-year of the index procedure for a provisional vs. two-stent strategy were 1.12 (0.42-3.02), 0.57 (0.37-0.87), 0.91 (0.61-1.35), and 0.56 (0.23-1.35), respectively. By quantitative coronary angiography, there was no difference in the difference in means (95% CI) between the provisional and two-stent strategies for percent diameter stenosis (95% CI) in the main vessel or side branch, -1.08 (-2.91 to 0.74) and 1.30 (-3.35 to 5.96), respectively.

Conclusion: While death, stent thrombosis, and restenosis were similar between the treatment groups, MI was more common with the two-stent strategy. Thus, compared to a routine two-stent strategy, provisional stenting yields similar efficacy with superior safety and lower costs.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Coronary Angiography / methods
  • Coronary Angiography / statistics & numerical data
  • Death
  • Drug-Eluting Stents* / adverse effects
  • Equipment Design
  • Humans
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / mortality
  • Myocardial Revascularization / statistics & numerical data
  • Paclitaxel / administration & dosage
  • Paclitaxel / therapeutic use
  • Patient Selection
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Risk
  • Sirolimus / administration & dosage
  • Sirolimus / therapeutic use
  • Thrombosis / epidemiology
  • Treatment Outcome

Substances

  • Paclitaxel
  • Sirolimus